Atazanavir/cobicistat - Bristol-Myers Squibb/Gilead
Alternative Names: Atazanavir sulfate/cobicistat; ATV/GS9350; EvotazLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb; Gilead Sciences
- Class Antiretrovirals; Carbamates; Morpholines; Oligopeptides; Pyridines; Small molecules; Thiazoles; Urea compounds
- Mechanism of Action Cytochrome P-450 enzyme system inhibitors; HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 11 Feb 2022 Bristol-Myers Squibb plans a phase I trial in Healthy volunteers in USA (PO, Tablet) in February 2022 (NCT05236738)
- 09 Sep 2021 Bristol-Myers Squibb completes a phase I trial for Healthy volunteers in USA (PO) (NCT02307656)
- 20 May 2021 Preregistration for HIV-1 infections (Combination therapy, In adolescents, In adults) in European Union (PO)